The company takes a methodical approach to ADC development, using both novel and clinically validated monoclonal antibodies (mAbs) armed with warheads from their proprietary payload platform or with off-the-shelf linker payload combinations. Pheon's lead program targets a novel highly expressed target in a broad range of solid tumors and is expected to reach IND within the next 18 months. The company is backed by expert healthcare investors and has state-of-the-art laboratories in London and a commercial office in Boston.